Arab Israeli Conflict
Hi Tech News
As you can imagine, more people are reading The Jerusalem Post than ever before.
Nevertheless, traditional business models are no longer sustainable and high-quality publications,
like ours, are being forced to look for new ways to keep going. Unlike many other news organizations,
we have not put up a paywall. We want to keep our journalism open
and accessible and be able to keep providing you with news
and analyses from the frontlines of Israel, the Middle East and the Jewish World.
As one of our loyal readers, we ask you to be our partner.
For $5 a month you will receive access to the following:
Help us grow and continue telling Israel’s story to the world.
Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief
Drugmaker AstraZeneca PLC said Wednesday that it has filed a lawsuit in a US court against Teva Pharmaceutical Industries Ltd. over a patent challenge to one of its key drugs from its Israeli rival.
The Anglo-Swedish company said it had begun action in US District Court in New Jersey against Teva for "willful infringement" of the substance patent that protects its best-selling schizophrenia treatment Seroquel.
The lawsuit is a response to an application filed by Teva in late September with the US Food and Drug Administration to market a generic version of a 25 milligram tablet version of the drug in the United States before AstraZeneca's patent expires in 2011.
"AstraZeneca has full confidence in and will continue vigorously to defend and enforce its intellectual property rights protecting Seroquel," the company said in a statement to the London Stock Exchange.
By GLOBES, NIV ELIS
By AARON KATSMAN
By NIV ELIS
By ARIEL SHAPIRA
By LEON HARRIS
Please insert a valid email address